latest news releases from the newsroom
OpVista Introduces Highly-Scalable ROADM-based Switched Ring Architecture (SRA)
CHICAGO, June 7, 2005 (PRIMEZONE) -- SUPERCOMM Booth No. 38081 -- OpVista, Inc., the company delivering high-capacity, low-cost Ultra-DWDM networks, announced the introduction of its scalable ROADM-based Switched Ring Architecture (SRA(tm)). SRA enables service providers (Cable MSO, telcos, CLECs) to build regional optical transport networks with the reconfigurability, scalability, and traffic pattern flexibility required for advanced video and IP services.
U.S. Authorities Honor Autoliv Researcher
STOCKHOLM, Sweden, June 7, 2005 (PRIMEZONE) -- The U.S. agency National Highway Traffic Safety Administration (NHTSA) has awarded Jan Olsson its Safety Engineering Excellence Award. He has worked for Autoliv -- the worldwide leader in automotive safety systems -- for eighteen years and has been instrumental in the development of many of the most important safety systems in today's vehicles. He received NHTSA's prestigious award ``for unique innovations and visionary leadership in crash safety development".
AudioDev to Deliver Signal Test Equipment for Xbox 360
MALMO, Sweden, June 7, 2005 (PRIMEZONE) -- As earlier announced, AudioDev AB and Microsoft Corporation (MSFT) have renewed the agreement for AudioDev to provide test equipment for the Xbox 360(R) video game and entertainment system from Microsoft. The agreement expands an ongoing development and purchase relationship between the two companies. As part of this agreement, AudioDev has now started deliveries of test equipment for Xbox 360.
TeliaSonera signs Nordic agreement with Stora Enso
STOCKHOLM, Sweden, June 7, 2005 (PRIMEZONE) -- Over the next few years TeliaSonera will be entrusted with taking care of Stora Enso's telecommunications in Sweden and Finland. The agreement signed with Stora Enso runs up to five years and covers fixed and mobile telephony, network solutions, PBX solutions and service.
Antisoma Starts Phase II Trial of AS1404 in Ovarian Cancer
LONDON, June 7, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has started a phase II trial of its vascular disrupting agent AS1404 in recurrent ovarian cancer. This is the third and final trial in a series evaluating AS1404 in combination with chemotherapy drugs. Phase II studies in lung and prostate cancers are ongoing, with the first efficacy data expected from the lung study during the second half of this year.